When will keytruda biosimilar launch in europe?

When does a Keytruda (pembrolizumab) biosimilar launch in Europe?

A Keytruda biosimilar launch date in Europe depends on two layers of protection: (1) regulatory approval timing for any submitted biosimilar and (2) whether marketing authorisation is allowed after expiry of the underlying exclusivity/patent barriers for pembrolizumab. The timing can shift as court cases and patent challenges play out.

As a starting point for the latest patent and exclusivity landscape that can affect launch timing, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/keytruda-1

Which biosimilar’s European launch date are people referring to?

People commonly ask about the first “true” pembrolizumab biosimilar to enter EU markets. Exact launch timing depends on which candidate you mean (for example, a specific developer’s biosimilar product and its European regulatory status), and whether it is able to market immediately or only after a regulatory/competitor settlement window.

What determines the exact month and year?

Even if a biosimilar candidate receives a positive EU regulatory view, launch can still be delayed by:
- patent expiry dates and granted/active patent coverage around Keytruda,
- litigation outcomes (for example, whether a court allows earlier marketing),
- and whether the biosimilar is cleared to commercialise versus held back until the legal barriers are lifted.

That’s why launch timelines are often reported as “earliest possible” dates tied to patent/exclusivity status rather than a single fixed year.

How can you check the most up-to-date EU launch expectations?

For the most current Europe-relevant dates and patent linkage information, DrugPatentWatch tracks Keytruda’s intellectual property status and notes where exclusivity could constrain biosimilar entry: https://www.drugpatentwatch.com/p/keytruda-1

---

Sources

1. https://www.drugpatentwatch.com/p/keytruda-1